Clovis Oncology, Inc. CLVSQ

Market cap
$14.2M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Sep '22 Jun '22 Mar '22 Dec '21 Older periods
ROE
78.31% 91.63% 98.57% 120.90%

+8 more TTM periods

ROA
(58.94%) (54.57%) (51.66%) (49.06%)
ROIC
0.00% (73.03%) (65.22%) (71.85%)
Return on Tangible Assets
39.31% (997.42%) (370.81%) (333.04%)
Average Days of Receivables
53.38 48.32 68.73 65.93
Free Cash Flow per Share
(1.22) (1.26) (1.40) (1.70)
Free Cash Flow
(175.84) (181.30) (192.92) (196.37)
Capital Expenditures
(0.27) (0.27) (0.26) (0.31)
Piotroski F-Score
2.00 2.00 4.00 3.00
Other line items
Cash ROIC
(183.76%) (47.97%) (42.48%) (40.57%)
Accounts Receivable Turnover
5.88 6.56 5.91 5.57
Accounts Payable Turnover
1.76 1.64 1.80 1.44
Inventory Turnover
2.58 2.00 2.11 1.75
Average Days of Payables
178.95 231.46 211.02 256.72
Days of Inventory on Hand
112.75 126.41 137.05 128.68
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
113.73% 118.85% 121.45% 125.44%
Selling, General and Administrative Expense of Revenue
94.37% 90.78% 88.08% 86.32%
Share Based Compensation of Revenue
18.02% 18.60% 19.35% 17.11%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.70 0.69 0.75 0.74
Depreciation/Fixed assets
2.05 1.88 1.76 1.67
Capex/Depreciation
(0.03) (0.03) (0.02) (0.03)
Revenue per Share
0.92 0.97 1.05 1.29
Operating CF per Share
(1.21) (1.26) (1.39) (1.70)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
(189.37%) (187.70%) (178.28%) (177.82%)

Fold the line items

Columns are period end dates